Search

everythinglearnresearchcommunity

for

Search:↓

Advanced therapies like gene, cell, and tissue engineering show promise for hair regrowth in alopecia, but their safety and effectiveness need more verification.

Certain microRNAs may help treat alopecia areata by targeting immune pathways.

Regenerative therapies show promise for treating vitiligo and alopecia areata.

Targeting SOX proteins may improve cancer treatment by restoring immune function.

Combining triamcinolone acetonide and immunotherapy can help regrow hair in some alopecia totalis patients.

Proper diagnosis is crucial to avoid overtreatment and complications in pregnant women with hyperthyroidism.

imTA and pulse therapy are effective for alopecia areata with manageable side effects, but relapse rates need improvement.

The boy's severe skin disorder is caused by two new mutations in his TGM1 gene.

Ketogenic diet, neurosteroids, and HMGB1-TLR4 signaling pathway are potential targets for new epilepsy treatments.

Personalized treatments for hair loss focus on specific genetic and biological pathways.

New drugs targeting the JAK-STAT pathway show promise for treating inflammatory skin diseases.

New treatments for Alopecia Areata, like JAK inhibitors, show promise for hair regrowth and are likely to change future treatment approaches.

Oral tofacitinib may effectively treat hair loss in children with alopecia areata.

New treatments like JAK inhibitors offer hope for better alopecia areata management.

Targeting specific T cells may help treat alopecia areata.

Removing a methyl group from the ITGAV gene speeds up bone formation in a specific type of bone disease model.

Interferons are effective for some skin conditions and cancers, but can have side effects and need more research for optimal use.

New targeted therapies for psoriasis show promise but face challenges like side effects and treatment resistance.

Targeting specific molecular pathways may improve treatments for chemoresistant cancers.

Topical immunotherapy is the best treatment for severe alopecia areata.

Thalidomide improved lupus symptoms but caused nerve damage in some patients.

UTMD with diclofenac and Doxil® improves cancer treatment by boosting immune response and reducing tumor-supporting cells.

Various local treatments for alopecia areata show promise, but individualized plans and more research are needed.

Betamethasone activates and increases the growth of certain skin cells from hair follicles.

TICE salvage chemotherapy is effective for treating germ-cell tumors with poor prognosis.

Composite biomaterials can precisely control immune responses for better disease treatment.

Dexamethasone reduces inflammation and delays skin cell changes caused by TPA.

Thymoma-associated multiorgan autoimmunity can cause liver damage and affects multiple organs, with limited treatment options and a generally poor prognosis.

Poor response to topical immunotherapy in alopecia areata patients is linked to impaired cell responses.

Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.